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Abstract 
Background and Purpose: 
Stenting for symptomatic carotid stenosis (CAS) carries a higher risk of procedural stroke or 
death than endarterectomy (CEA). It is unclear whether this extra risk is present both on the 
day of procedure and within 1-30 days thereafter and whether clinical risk factors differ 
between these periods. 
Methods: 
We analyzed the risk of stroke or death occurring on the day of procedure (immediate 
procedural events) and within 1-30 days thereafter (delayed procedural events) in 4597 
individual patients with symptomatic carotid stenosis who underwent CAS (n=2326) or CEA 
(n=2271) in four randomized trials. 
Results: 
Compared with CEA, patients treated with CAS were at greater risk for immediate procedural 
events (110 versus 42, 4.7% versus 1.9%; OR 2.6, 95% CI 1.9-3.8), but not for delayed 
procedural events (59 versus 46, 2.5% versus 2.0%, OR 1.3, 0.9-1.9; interaction p=0.006). In 
patients treated with CAS, age increased the risk for both immediate and delayed events, 
while qualifying event severity only increased the risk of delayed events. In patients treated 
with CEA, we found no risk factors for immediate events, while a higher level of disability at 
baseline and known history of hypertension were associated with delayed procedural events.  
Conclusions: 
The increased procedural stroke or death risk associated with CAS compared with CEA was 
caused by an excess of events occurring on the day of procedure. This finding demonstrates 
the need to enhance the procedural safety of CAS by technical improvements of the procedure 
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and increased operator skill. Higher age increased the risk for both immediate and delayed 
procedural events in CAS, mechanisms of which remain to be elucidated. 
Clinical Trial Registration: 
EVA-3S - URL: https://clinicaltrials.gov/ct2/show/NCT00190398; Unique identifier: 
NCT00190398.  
SPACE - URL: http://www.isrctn.com/ISRCTN57874028; Unique identifier: 
ISRCTN57874028.  
ICSS - URL: http://www.isrctn.com/ISRCTN25337470; Unique identifier: 
ISRCTN25337470.  
CREST- URL:https://clinicaltrials.gov/ct2/show/NCT00004732; Unique identifier: 
NCT00004732. 
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Introduction 
In patients with recently symptomatic carotid stenosis, carotid artery stenting (CAS) is 
associated with a higher risk of stroke or death in the procedural period (defined as within 30 
days of treatment) than endarterectomy (CEA).1 This extra risk associated with stenting is 
mostly attributed to an increase in minor or non-disabling strokes occurring in patients older 
than 70 years.1, 2  Beyond the procedural period, stenting seems to be as effective as 
endarterectomy in preventing recurrent stroke.3-5 Within the 30-day procedural period, it has 
been unclear whether the extra risk associated with stenting is present both on the day of 
procedure and within 30 days thereafter.  
 
The Carotid Stenosis Trialists’ Collaboration (CSTC) pooled data of individual patients with 
symptomatic carotid stenosis enrolled in the Endarterectomy Versus Angioplasty in patients 
with Symptomatic Severe Carotid Stenosis trial (EVA-3S), the Stent-Protected Angioplasty 
versus Carotid Endarterectomy trial (SPACE), the International Carotid Stenting Study 
(ICSS) and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). All 
trials have completed their long-term follow-up and the results have been published.3-6  
 
In the present analysis, we compared the risk of stroke or death occurring on the day of 
procedure and within 1-30 days following both treatments. In addition, we investigated if 
clinical risk factors for stroke or death differed between these periods.  
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Methods 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. This meta-analysis includes individual patient data from EVA-3S 
(NCT 00190398), SPACE (ISRCTN 57874028), CREST (NCT00004732) and ICSS 
(ISRCTN 25337470). Patients were recruited from 2000-2005 in EVA-3S, from 2001-2006 in 
SPACE, from 2001-2008 in ICSS, and from 2000-2008 in CREST. Ethics approval for the 
contributing trials was obtained at the competent institutional review boards and all patients 
provided written informed consent. The pooled analysis of individual patient data was agreed 
upon at the design stage of these trials.7 All four trials were randomized clinical trials with 
blinded outcome adjudication. Detailed inclusion and exclusion criteria of all trials have been 
reported previously.8-11 In summary, all trials included patients with symptomatic moderate to 
severe carotid stenosis (≥50% reduction of lumen diameter measured according to the method 
used in the North American Symptomatic Carotid Endarterectomy Trial [NASCET]), who 
were equally suitable for either procedure. CREST additionally included patients with 
asymptomatic carotid stenosis, but only data from symptomatic patients were included in the 
present analysis. Patients were randomly allocated in equal proportions to CAS or CEA.9, 11-13  
 
In EVA-3S, SPACE and ICSS all stents had to be CE (Communauté Européenne) marked. In 
CREST, the protocol specified the use of the RX Acculink stent. In EVA-3S, the use of distal 
filter protection devices became mandatory early in the trial, after the risk of stroke within the 
procedural period was found to be unacceptably high in patients treated with unprotected 
CAS. In CREST, the use of the RX Accunet embolic protection device was recommended 
whenever feasible. In ICSS and SPACE, the use of protection devices remained optional 
throughout the trials. Surgeons could perform standard or eversion endarterectomy under 
local or general anesthesia, with or without the use of shunts or patches. CAS or CEA was 
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deemed initiated if the patient had been given general or local anesthetic in preparation for the 
intervention. 
 
The primary outcome event for this analysis was stroke or death occurring either on the day of 
treatment (immediate procedural event) or within 1-30 days thereafter (delayed procedural 
event). Stroke was defined as an acute deficit of focal neurological function which led to 
symptoms lasting longer than 24 hours, resulting from intracranial vascular disturbance 
(ischemia or hemorrhage). For the present analysis, only the first event was considered, 
because we assumed that second events (e.g. death or another stroke occurring after a first 
stroke) would rarely be independent of the first event. In addition, second events of the same 
type occurring in the peri-procedural may not have been reported separately in the source 
trials. 
 
Statistical analysis 
The primary analysis population included all patients in whom the randomly allocated 
treatment was initiated (per-protocol analysis).1 Patients crossing over to the other treatment, 
those who did not receive either treatment, and those who died before treatment were 
excluded. A per-protocol analysis rather than intention-to-treat analysis was chosen because 
the main difference between the two analysis populations consisted of patients who did not 
receive either treatment (Figure 1). In addition, the primary aim of our research question was 
to investigate whether the risk of stroke or death differed between CAS and CEA in two 
distinct time periods (day of treatment and 1-30 days after treatment).  
 
Data were analyzed with generalized linear mixed-effects models (GLMM) with binomial 
error and logit link function, with a random intercept for each source trial. The CAS versus 
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CEA treatment effect was expressed as an odds ratio (OR) with 95% confidence interval (CI), 
both for immediate procedural events and for delayed procedural events, with CEA as the 
reference treatment. To investigate whether the CAS versus CEA treatment effect differed 
between the immediate and delayed procedural period, we reshaped the analysis set to include 
two observations (rows) per patient, one for immediate procedural events and one for delayed 
procedural events, and included a random intercept for each source trial and patient. We chose 
this approach to be able to investigate whether the odds ratio for the primary outcome differed 
between the immediate and the delayed procedural period by formal testing of statistical 
interaction. We did this by including treatment (CAS versus CEA), time of event (immediate 
versus delayed) and an interaction term between treatment and time in the model. We 
performed a sensitivity analysis excluding patients who had the primary outcome event in the 
immediate procedural period from the population at risk in the delayed procedural period. 
 
We investigated if the following baseline patient characteristics were associated with stroke or 
death in the immediate (day 0), the delayed (day 1-30) and the full procedural period (day 0-
30) by a forward variable selection approach based on the Akaike information criterion (AIC), 
in each treatment group separately: patient age and sex, systolic blood pressure at baseline, 
previous diagnosis of hypertension, diabetes mellitus, hyperlipidemia or coronary heart 
disease, any history of smoking (current or past), modified Rankin Scale at baseline, degree of 
ipsilateral stenosis measured according to NASCET criteria14 dichotomized into moderate 
(50-69%) or severe (70-99%), presence of contralateral stenosis (>50%) according to 
NASCET criteria14 or occlusion, and severity of the qualifying event (analyzed by trend: 
hemispheric ischemic stroke > transient ischemic attack [TIA] > ocular ischemia [including 
amaurosis fugax or retinal infarction]). Qualifying event severity was analyzed by trend 
because patients with previous ocular events have a lower risk of future ischemic stroke 
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compared to patients who had a TIA, and patients with a TIA have a lower risk than patients 
who had a hemispheric stroke.15 
 
To investigate if associations between patient characteristics and procedural events differed 
between the immediate and the delayed procedural period, we again used the data structure 
with two observations per patient (using the subset with CAS or CEA) and included baseline 
patient characteristics which were associated with immediate or delayed procedural events 
and their interactions with time.  
 
In addition, we fitted a GLMM for the immediate, the delayed and the full procedural period 
each, adjusted for any variables identified as significant predictors of the primary outcome 
event in any of these periods by the forward selection approach described above. We used 
these models to display the risk factor associations for the different periods in a forest plot.  
 
A p-value of <0.10 for interaction terms was considered statistically significant. For all other 
statistical analyses, a p-value of <0.05 was considered to indicate statistical significance. All 
statistical analyses were performed as complete case analyses (no imputation of missing 
values), using the statistical software environment R (Version 3.4.1; R Foundation for 
Statistical Computing, Vienna, Austria). 
 
Results 
In total 4,775 patients with symptomatic carotid stenosis were enrolled in the four 
contributing trials. The pooled per-protocol analysis set included 4,597 patients, 2,271 of 
whom received CEA and 2,326 CAS. Reasons for exclusion of patients from the per-protocol 
analysis are provided in Figure 1. Baseline characteristics were well balanced between the 
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stenting and the endarterectomy group (Table 1). In ICSS, SPACE and EVA-3S closed-cell 
stents were used in 61.8%, while in CREST the use of the open-cell RX Acculink stent device  
was mandatory. In CREST 96.1% of patients were treated with the RX Accunet embolic 
protection device, while in ICSS, SPACE and EVA-3S 61% of patients were treated with 
various embolic protection devices (Supplemental table I). 
 
A total of 257 patients had a stroke or died during the full 30-day procedural period, 169 in 
the CAS group (7.3% risk) and 88 in the CEA group (3.9% risk; OR 1.94, 95% CI 1.48-2.54). 
Compared with CEA, patients treated with CAS more often had a stroke or died on the day of 
procedure (110 versus 42 patients, 4.7% versus 1.9% risk; OR 2.64, 95% CI 1.85-3.78), but 
not between 1 and 30 days thereafter (59 versus 46 patients, 2.5% versus 2.0% risk, OR 1.26, 
0.86-1.87; Figure 2). The treatment effect ORs differed significantly between the time periods 
(interaction p=0.006). We performed a post-hoc sensitivity analysis excluding all patients 
who experienced the outcome measure on the day of procedure (n=152) from the population 
at risk for an event between day 1-30. This yielded very similar results compared to our 
original model and we again found no significant difference in the occurrence of the outcome 
measure between CAS and CEA between day 1-30 (OR 1.30, 95% CI 0.87-1.91). Only two 
patients who had a stroke on day 0, had another stroke between day 1-30. 
 
Details of outcome events are provided in Table 2. In both treatment groups, the large 
majority of strokes, both occurring on the day of procedure and between day 1 and 30 after 
procedure, were located in the territory supplied by the treated carotid artery. In both 
treatment groups combined, 2 of 151 strokes (1%) occurring on the day of procedure and 15 
of 95 strokes (16%) occurring between day 1 and 30 after the procedure were of hemorrhagic 
type. 
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In the stenting group, the forward selection model identified age and smoking as independent 
predictors of immediate procedural events:  age was positively (OR 1.54 per decade, 95% CI 
1.21-1.95 per decade) and smoking was negatively (OR 0.61, 95% CI 0.40-0.91) associated 
with stroke or death occurring on the day of treatment. For the delayed procedural period (day 
1-30 after treatment) age (OR 1.63 per decade, 95% CI 1.21-2.21) and qualifying event (QE) 
severity (stroke > TIA > ocular ischemia, analyzed by trend; OR 1.54, 95% CI 1.03-2.31) 
were found to be significant predictors for stroke or death. There were no significant 
differences in the strength of the associations between these risk factors and events between 
the immediate and delayed procedural period with the exception of smoking (interaction 
p=0.061; Figure 3). For the entire procedural period both age (OR 1.05, 95% CI 1.03-1.07) 
and QE severity (analyzed by trend; OR 1.31, 95% CI 1.04-1.64) remained significant 
predictors for stroke or death occurring between day 0-30 after treatment.  
 
In the endarterectomy group, we found no significant predictors for immediate stroke or 
death. However, a higher level of disability at baseline, assessed with the modified Rankin 
Scale, was a significant predictor for delayed stroke or death (OR 1.42, 95% CI 1.10-1.84). 
The association between this risk factor and procedural stroke or death did not differ 
significantly between the immediate and delayed procedural period (Figure 4). Higher level of 
disability at baseline and history of hypertension were found to be significant predictors for 
stroke or death in the full procedural period (OR 1.24, 95% CI 1.01-1.51, and OR 1.84, 95% 
CI 1.04-3.33, respectively).  
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Discussion 
In this pooled analysis of individual patient data from four randomized clinical trials, we 
found that the excess occurrence of procedural stroke or death associated with CAS compared 
with CEA was limited to the day of treatment. For the remainder of the procedural period, 
there was no difference in the risk of stroke or death between the two treatments. Age was a 
risk factor for stroke or death in the CAS group, notably both in the immediate (day of 
procedure) and the delayed procedural period (day 1-30). 
 
Procedure-related stroke or death in carotid revascularization is commonly defined as all 
events occurring within 30 days after the procedure. However, from experience, most such 
events occur on the day of treatment. In our analysis, we were able to confirm this 
assumption. We found that about two thirds (110 out of 169) of all procedural stroke or death 
outcomes in patients receiving CAS and about half (42 out of 88) of the events in patients 
treated with CEA occurred on the day of procedure. On the day of procedure, the risk of 
procedural stroke or death was significantly higher in CAS than in CEA, but between 1 and 
30 days thereafter the risk was similar in both treatment groups. 
 
Stroke or death events occurring on the day of procedure might differ in pathogenesis and 
associated risk factors from events occurring later in the 30-day period. However, as far as 
clinical risk factors are concerned, we found no significant differences in the observed 
associations between the immediate and delayed procedural period. Most importantly, 
increasing age among patients treated with CAS was significantly associated with procedural 
stroke or death in both the immediate (day of procedure) and delayed procedural (day 1-30) 
period. It has been hypothesized that higher age is associated with vessel elongation and 
therefore more pronounced angulation of the vasculature, and that the resulting, more 
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complex anatomy of the supra-aortic arteries could lead to increased technical difficulty of the 
procedure and hence to the higher risk associated with CAS in older patients.16, 17 Our finding 
that age is associated with an increase in both immediate and delayed procedural events 
argues against vascular anatomy as the sole mediating factor. Older patients might have more 
unstable atheromatous lesions than younger patients, which may cause thromboembolic 
strokes not only on the day of procedure, but also during the following days.18, 19 However, 
the mechanisms mediating the association between age and procedural risk of CAS remains 
poorly understood; our finding that older patients are also at risk for delayed procedural 
events adds to the complexity of this matter.  
 
Interestingly, we found that history of smoking decreased the risk for stroke or death on the 
day of procedure in the CAS group. A similar association with stroke or death in the full 
procedural period was already described in ICSS.20 One possible explanation for this rather 
surprising relationship might have been that smokers were younger than non-smokers and 
hence at lower risk. Indeed, the mean age of smokers in our study population was 67.5 years, 
while the mean age of non-smokers was 72.5 years.  However, the effect of smoking was 
adjusted for age in our analysis indicating that the inverse association with stroke or death is 
not confounded by age. Nevertheless, we cannot rule out that this unexpected finding was due 
to residual confounding by patient characteristics not measured in the trials.  
 
The fact that the excess of procedural stroke or death occurring in the stenting group is limited 
to the day of procedure suggests that these events might potentially be avoided by improving 
operator skill or technical aspects of the procedure itself. Whether the use of intraluminal 
protection devices reduces the risk of embolic stroke is a matter of ongoing controversy. In 
EVA-3S the use of distal filter protection devices became mandatory early in the trial, after 
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the risk of stroke within the procedural period was found to be about three times higher in 
patients treated with unprotected CAS. In CREST the use of cerebral protection devices was 
recommended whenever feasible. In ICSS and SPACE the use of protection devices remained 
optional throughout the trials. The ICSS-MRI substudy showed that the use of distal filter 
devices, which was the type of protection device predominately used in all four contributing 
trials, was associated with an increased risk of new ischemic brain lesions after the 
procedure.21 Two small randomized studies comparing stenting with embolic filter protection 
to unprotected stenting confirmed these results.22, 23 In light of these findings, considerable 
uncertainty remains, whether distal filter devices truly increase the safety of CAS.  
 
Irrespective of this question, one must acknowledge the fact that the trials contributing to the 
present analysis largely enrolled their patients in the 2000s and that considerable technical 
advance of CAS has occurred since. For example, alternative methods of cerebral protection 
such as systems exerting a reversal of blood flow before the lesion is crossed with the catheter 
have been introduced and appear to lower the risk of thromboembolism.24 However, not all 
patients tolerate flow reversal in the carotid artery and to date insufficient data exist to justify 
a general recommendation for the use of such devices, although the available data seem 
promising.25, 26 The ARMOUR study investigated the safety and effectiveness of proximal 
embolic protection with the Mo.MA device and showed a very low 30-day stroke rate of 
0.9%.26 Another possible source of thromboembolism to the brain during stenting is the aortic 
arch and the access vasculature. To avoid the necessity of navigating the aortic arch with 
potentially difficult anatomy, alternative access routes such as direct carotid access have been 
proposed.27 The ROADSTER study investigating CAS with direct transcarotid access and 
proximal embolic protection showed a very low 30-day stroke rate of 1.4%.28 Although the 
ARMOUR and the ROADSTER studies enrolled patients with both symptomatic and 
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asymptomatic carotid stenosis, which renders a direct comparison with our results difficult, 
these low stroke rates are remarkable.  
 
In the endarterectomy group, the only clinical risk factors found to influence the risk of stroke 
or death were a higher level of disability at baseline and known history of hypertension. 
Hypertension increased the risk for stroke or death over the entire procedural period of 30 
days, a finding which is consistent with previous reports.15 
 
This analysis has important limitations. First, we did not collect information as to the 
mechanism of stroke across all four contributing trials (e.g. embolic, hemodynamic, stent 
thrombosis). Second, with regard to events occurring on the day of treatment, we do not know 
if the events occurred during or after the procedure, as the exact timing of stroke or death was 
not recorded. Third, all participating trials recruited patients between 2000 and 2008. Since 
that time, there has been substantial progress in the development of new stent designs, the 
introduction of cerebral protection devices and new access routes, all of which may help 
reduce the risk of immediate procedural complications. Thus, the peri-procedural stroke rate 
among patients with symptomatic carotid stenosis using current generation CAS technologies 
and cerebral protection devices may be lower than demonstrated in these 4 trials. Fourth, in 
order to be able to investigate whether the CAS versus CEA treatment effect differed between 
the immediate and delayed procedural period by formal tests of statistical interaction, we 
included all patients in the population at risk for an event between day 1-30, even those who 
experienced an event on the day of procedure (n=152). However, in a post-hoc analysis 
excluding the patients with an event on day 0 (n=152) from the population at risk for an event 
between day 1-30, the results remained essentially unchanged.  
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The fact that the increased risk of stroke or death in the stenting group is limited to the day of 
procedure demonstrates the need to improve the procedural safety of carotid artery stenting. 
This may potentially be achieved by technical advances (route of access, stent design and new 
protection devices) and increased operator skill. However, more data from randomized trials 
to evaluate these new devices and access routes are needed. Our finding that age is associated 
with both immediate and delayed procedural events in the stenting group argues against 
vascular anatomy as the sole mediating factor. Other, currently unknown factors are likely to 
contribute to this effect and remain to be elucidated. 
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Figure legends 
Figure 1 - flow chart. Study flow chart depicting all patients in the source trials included in 
this meta-analysis as well as events that precluded them from analysis.  
 
Figure 2 – Kaplan-Meier curve. Kaplan-Meier curve of the cumulative incidence of 
periprocedural stroke or death within 30 days after treatment in the stenting and 
endarterectomy group seperately. Number of events: 169 events in the CAS group, 88 events 
in the CEA group. The cumulative incidence of stroke or death was 7.3% in the CAS group 
and 3.9% in the CEA group. 
 
Figure 3 - Effects of baseline variables on the risk of stroke or death in patients treated 
with carotid artery stenting. Forest plot showing the odds ratios for the effects of the three 
baseline variables “patient age” (in decades, not years), any “history of smoking”, and 
“qualifying event severity” on the incidence of stroke or death on the day of treatment (day 
0), between day 1 and 30, or within 30 days in patients treated with stenting. ORs were 
estimated by three separate GLMMs (one for the day of treatment, one for day 1- 30, and one 
for the full procedural period), each containing age, any history of smoking, and QE severity 
(stroke > TIA > ocular ischemia). CI=Confidence Interval; OR=Odds Ratio; p (int) = 
interaction p-value; QE=Qualifying event; GLMM=general linear mixed model.  
 
Figure 4 - Effects of baseline variables on the risk of stroke or death in patients treated 
with carotid endarterectomy. Forest plot showing the odds ratios for the effects of the 
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baseline variable “mRS at baseline”, and “history of hypertension” on the incidence of 
stroke or death on the day of treatment (day 0), between day 1 and 30, or within 30 days in 
patients treated with endarterectomy. ORs were estimated by three separate GLMMs (one for 
the day of treatment, one for day 1-30, and one for the full procedural period). OR=Odds 
ratio; CI=confidence interval; p (int) = interaction p-value; GLMM=general linear mixed 
model; mRS=modified Rankin Scale 
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Tables  
Table 1. Patient characteristics at baseline 
 CEA 
(n = 2271) 
CAS 
(n = 2326) 
Male n (%) 1593/2271 (70.1%) 1615/2326 (69.4%) 
Age years (mean, SD) 69.4 ± 9.2 69.2 ± 9.2 
Systolic blood pressure mmHg (mean, SD) 142.8 ± 21 143.9 ± 21 
Hypertension n (%) 1718/2264 (75.9%) 1743/2264 (75.3%) 
Diabetes n (%) 576/2270 (25.4%) 575/2325 (24.7%) 
Hyperlipidemia* or LLT n (%) 1471/2271 (64.7%) 1462/2326 (62.9%) 
LLT 1443/2271 (63.5%) 1439/2326 (61.9%) 
Smoking (current or past) n (%) 1472/2254 (65.3%) 1489/2308 (64.5%) 
Coronary artery disease n (%) 630/2218 (28.4%) 626/2276 (27.5%) 
mRS at baseline n (%) 
0 n (%) 1133/2252 (50.3%) 1167/2305 (50.6%) 
1 n (%) 587/2252 (26.1%) 622/2305 (27.0%) 
2 n (%) 365/2252 (16.2%) 358/2305 (15.5%) 
>2 n (%) 167/2252 (7.4%) 158/2305 (6.9%) 
Degree of ipsilateral carotid stenosis 
Moderate (50-69%) n (%) 443/2271 (19.5%) 441/2326 (19%) 
Severe (70-99%) n (%) 1828/2271 (80.5%) 1885/2326 (81.0%) 
Contralateral stenosis or occlusion 301/2037 (14.8%) 308/2326 (14.8%) 
Qualifying event type 
Ocular ischemia n (%) 388/2256 (17.2%) 394/2312 (17.0%) 
Transient ischemic attack n (%) 835/2256 (37.0%) 847/2312 (36.6%) 
Hemispheric stroke n (%) 1033/2256 (45.8%) 1071/2312 (46.3%) 
Days from QE to treatment median (IQR)† 29.0 (13.0, 67.0) 26.0 (11.0, 61.0)  
Treatment within 7 days of QE n (%) † 214/1907 (11.2%) 277/1926 (14.4%) 
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Baseline data of patients in the stenting and endarterectomy group. Percentages exclude 
missing data. CEA = carotid endarterectomy; CAS = carotid artery stenting; LLT = lipid 
lowering therapy: EVA-3S recorded LLT use at baseline but patients were only considered to 
be taking LLT if started >3months prior to randomization. SPACE and CREST collected data 
on LLT use at randomization. ICSS did not collect information on LLT use at baseline but did 
collect these data at the one-month follow-up, which were included in the table. QE = 
qualifying event; SD = standard deviation.*Data were not collected in SPACE. †Date of the 
qualifying event before randomization was not collected in the SPACE trial initially, but for 
the pooled analysis, these dates were gathered where available. 
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Table 2. Outcome events occurring on the day of procedure vs. day 1-30 thereafter 
 CAS 
(n=2326) 
CEA 
(n=2271) 
Total 
(n=4597) 
 Day of procedure Day 1-30 Day of procedure Day 1-30 Day of procedure Day 1-30 
Any stroke n(%) 109  52 42 43 151 95 
Ipsilateral  100 (92%) 47 (90%) 42 (100%) 37 (86%) 142 (94%) 84 (88%) 
Non-ipsilateral  9 (8%) 5 (10%) 0 (0%) 6 (14%) 9 (6%) 11 (12%) 
Ischemic stroke n (%) 108 (99%) 48 (92%) 41 (98%) 32 (74%) 149 (99%) 80 (84%) 
Hemorrhagic stroke n (%) 1 (1%) 4 (8%) 1 (2%) 11 (26%) 2 (1%) 15 (16%) 
Non-stroke death  1 7 0 3 1 10 
 
Data are numbers and percentages of patients who experienced an outcome event. CAS = carotid artery stenting; CEA = carotid endarterectomy. 
